Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 190Lung Neoplasms 67Ovarian Neoplasms 64Breast Neoplasms 38Fallopian Tube Neoplasms 33Small Cell Lung Carcinoma 31Parkinson Disease 4, Autosomal Dominant Lewy Body 27Carcinoma, Ovarian Epithelial 24Uterine Cervical Neoplasms 22Triple Negative Breast Neoplasms 22Squamous Cell Carcinoma of Head and Neck 19Neuroblastoma 17Carcinoma 17Adenocarcinoma of Lung 17Neoplasm Metastasis 15Endometrial Neoplasms 14Neoplasms 12Head and Neck Neoplasms 11Recurrence 8Peritoneal Neoplasms 8Carcinoma, Transitional Cell 8Esophageal Neoplasms 7Central Nervous System Neoplasms 7Brenner Tumor 7Urinary Bladder Neoplasms 6Lung Diseases 6Adenocarcinoma, Bronchiolo-Alveolar 6Thoracic Neoplasms 5Testicular Neoplasms 5Respiratory Tract Neoplasms 5

Interventions

Carboplatin 2tislelizumab 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Advanced Non-squamous Non-small-cell Lung Cancer × Carboplatin × Clear all
NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 3 Recruiting
392 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

NCT04416035 2020-08-31

NSCLC

Zhejiang Teruisi Pharmaceutical Inc.

Phase 3 Unknown
608 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡